We made the cover of this @CR_AACR issue!!! 🥳🥳🥳 Published Paper: https://t.co/atadDRyh08 Rascore Website: https://t.co/ROK06DSNQR @RolandDunbrack @DrexelMcbg @FCCCAcademics

📜 Led by @MilitSPatel and Dr @IMRTLee, out in @NatRevClinOncol today: 👉 We highlight the importance of #synergy between #human #care and #AI-informed #medicine for people with #cancer. 👉 AI can #augment human expertise, not replace it. 🔗 https://t.co/nzdwn7qalh

Ten years (!) after submitting the grant, NextBrain is published in @Nature . NextBrain is a brain atlas built from 3D histology that enables segmentation of 3D brain scans (MRI, Hip-CT, even photos!) into hundreds of regions. Article, data, code, videos, & more in this 🧵 (1/3)

Grateful to share that our latest publication on reduced dose radiotherapy for high-risk neuroblastoma has been published in @IJROBP. https://t.co/2lLlRqcDiH

I’m very excited to participate as a panelist discussing the @GoogleAI Co-Scientist at this event, alongside Burak Gokturk, VP of AI Research and @ShwetaManiar from @googlecloud healthcare, and others. I’ve linked the registration site below for anyone interested in signing up.

I wonder what the final results will be 🤔 #ASTRO25 #radonc

Honored to train at ⁦@MSKCancerCenter⁩ #radonc alongside experts, change makers, and good people 🤩 #ASTRO2025 ⁦@ASTRO_org⁩ ⁦@DanielGorovets⁩ ⁦@seanmmcbride⁩ ⁦@KaitlynLapen⁩ ⁦@MSK_RadOnc⁩ Thank you to Melissa and Amelia for setting this up

Congratulations to our very own @Jake_Hogan_ already making waves in #ASTRO25 as recipient of the 2025 ARRO Health Care Access Publication Award for his study, “Radiotherapy Utilization in Traditional Medicare and Medicare Advantage” published in JAMA Network Open. Amazing work!!

Please join us on 9/24 to hear about the FCCC Radiation Oncology program! We’d love to meet you! #match2026 #radonc #radoncmatch

The #CoC #NCDB released the Hospital Comparison Benchmark Report, which allows hospitals to access their quality data in real time while potentially comparing this data to larger aggregates such as all CoC programs or programs within a state. https://t.co/vWXjdLbACZ

🩺✨ Intergration of @AbridgeHQ’s AI scribe into @HeyEpic’s Haiku app and EHR makes it such a good product to use. 📝 Dramatically improves my note quality ⏰ Given me precious time back with patients 🎯 Improves my entire documentation workflow @AbridgeHQ workflow in Haiku

Brain metastasis is an uncommon but devastating event for pts with colorectal cancer. In work led by Drs. Gui and Walch @hswalch, we identify genomic features, present at initial diagnosis, that may help identify pts likely to develop BM. @MSKCancerCenter

🚨ATTN: APPLICANTS! 🚨 Join our virtual open house to learn more about our program!

Congrats to our one and only star PGY-2 Sarthak Shah on completing his first rotation!

Distant failure after SBRT for oligometastatic disease is a common pattern of progression. Yet, we lack validated post-progression models to guide treatment. We tested whether Distant Metastasis Velocity (DMV) can fill this gap - and validated it across multinational cohorts 🧵

We'd like to welcome MSK's newest PGY-2 Radiation Oncology Residents. We're excited to watch their growth and contribute to the department and field. If you're interested in learning more about our program, join us for our Virtual Open Houses below: 📅 Wednesday, August 20th at

Published @Nature : Air pollution may drive TP53 and other mutations in lung cancer among never-smokers. EGFR was common in East Asia, KRAS in the West; secondhand smoke showed minimal genomic impact, and herbal toxin–linked signatures were seen in Taiwan.

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study Adding chemo to osimertinib may benefit patients w/ EGFR + TP53 (L858R) more than those w/ Exon 19 del https://t.co/ZbW3eFp9RX

🚨New preprint! 🚨In-context learning (ICL) is the intriguing ability of LLMs to learn to solve tasks purely from context w/o parameter updates. For multimodal LLMs (MLLMs), ICL is poorly understood, especially in the medical domain where doctors would often face few relevant

With AI-driven auto-contouring now routine, the role of radiation oncologists is shifting—from manual delineation to reviewing AI-generated contours. But how well does our inner compass detect which changes really impact OAR dose? 📊 We put this to the test in our new study.👇

❓ESTRO & EORTC proposed a classification to standardize reirradiation. But does it predict outcomes or toxicity? 🫁☢️ We applied the classification in thoracic reirradiation for NSCLC. Here’s what we found. 🧵